Grossarth-Maticek R, Kiene H, Baumgartner S M, Ziegler R
Institute for Preventive Medicine, European Center for Peace and Development, United Nations, Heidelberg, Germany.
Altern Ther Health Med. 2001 May-Jun;7(3):57-66, 68-72, 74-6 passim.
In anthroposophical medicine, total extracts of Viscum album (mistletoe) have been developed to treat cancer patients. The oldest such product is Iscador. Although Iscador is regarded as a complementary cancer therapy, it is the most commonly used oncological drug in Germany.
To determine whether Iscador treatment prolongs survival time of patients with carcinoma of the colon, rectum, or stomach; breast carcinoma with or without axillary or remote metastases; or small cell or non-small-cell bronchogenic carcinoma; and to explore synergies between Iscador treatment and psychosomatic self-regulation.
Prospective nonrandomized and randomized matched-pair studies nested within a cohort study.
General community in Germany.
10,226 cancer patients involved in a prospective long-term epidemiological cohort study, including 1668 patients treated with Iscador and 8475 who had taken neither Iscador nor any other mistletoe product (control patients).
Iscador.
Survival time.
In the nonrandomized matched-pair study, survival time of patients treated with Iscador was longer for all types of cancer studied. In the pool of 396 matched pairs, mean survival time in the Iscador groups (4.23 years) was roughly 40% longer than in the control groups (3.05 years; P < .001). Synergies between Iscador treatment and self-regulation manifested in a longer survival advantage for Iscador patients with good self-regulation (56% relative to control group; P = .03) than for patients with poor self-regulation. Results of the 2 randomized matched-pair studies largely confirmed the results of the non-randomized studies.
Iscador treatment can achieve a clinically relevant prolongation of survival time of cancer patients and appears to stimulate self-regulation.
在人智医学中，已研发出欧洲槲寄生（槲寄生）的全提取物用于治疗癌症患者。最古老的此类产品是Iscador。尽管Iscador被视为一种辅助癌症治疗方法，但它却是德国最常用的肿瘤药物。
确定Iscador治疗是否能延长结肠癌、直肠癌或胃癌患者；有或无腋窝或远处转移的乳腺癌患者；或小细胞或非小细胞支气管癌患者的生存时间；并探索Iscador治疗与身心自我调节之间的协同作用。
前瞻性非随机和随机配对研究嵌套在一项队列研究中。
德国普通社区。
10226名参与前瞻性长期流行病学队列研究的癌症患者，其中包括1668名接受Iscador治疗的患者和8475名既未服用Iscador也未服用任何其他槲寄生产品的患者（对照患者）。
Iscador。
生存时间。
在非随机配对研究中，接受Iscador治疗的患者在所有研究的癌症类型中的生存时间更长。在396对配对中，Iscador组的平均生存时间（4.23年）比对照组（3.05年）长约40%（P < 0.001）。Iscador治疗与自我调节之间的协同作用表现为，自我调节良好的Iscador患者的生存优势（相对于对照组为56%；P = 0.03）比自我调节差的患者更大。两项随机配对研究的结果在很大程度上证实了非随机研究的结果。
Iscador治疗可在临床上显著延长癌症患者的生存时间，并且似乎能刺激自我调节。
